Loading
Life sciences · Observational Study
ClinicalTrials.gov · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07556549). This is a study registration, not published results. Lead sponsor: Pfizer. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 50 participants (ACTUAL). Conditions: Non-Small Cell Lung Cancer ALK-positive. Interventions: DRUG: Lorlatinib. Primary outcome measures: Age at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Smoking status (if available) at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Histology of patients at start of Lorlatinib treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Eastern Cooperative Oncology Group (ECOG) performance status of patients at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Initial cancer stage at diagnosis of patients prior Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Current cancer stage at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Brain metastases status at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Date of initial NSCLC diagnosis , At initiation of lorlatinib treatment between July 2022- October 2024; Date of a/mNSCLC diagnosis , At initiation of lorlatinib treatment between July 2022- October 2024; ALK-positive diagnosis prior to Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Gene testing method and results prior to initiation of lorlatinib treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Date of brain metastases diagnosis prior to initiation of lorlatinib treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Presence of comorbidities at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Concomitant therapies at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Date of lorlatinib initiation , At initiation of lorlatinib treatment between July 2022- October 2024; Initial lorlatinib dose at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Dose adjustments when patients were prescribed with Lorlatinib Treatment , From the date of initiation of lorlatinib treatment to the date of treatment dose adjustments, assessed up to 50 months (where 50 months is the estimated maximum follow-up duration for this outcome).; Gender at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Weight at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Height at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024; Body mass index (BMI) at Start of Lorlatinib Treatment , At initiation of lorlatinib treatment between July 2022- October 2024. Brief summary: The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC. The participants included in this study are: * Aged 18 years or more * diagnosed with a/mNSCLC * confirmed with testing for ALK-positive * have started first-line lorlatinib treatment during the patient selection period In this study, the main objectives are to learn the patient characteristics and the real-world treatment pattern of first-line treatment of lorlatinib in China at a real-world setting.